Long-term use of diazepam.

Area of Science:

• Pharmacology
• Clinical Neuroscience

Background:

• Diazepam is frequently prescribed for neurosurgical patients to manage pain, muscle spasms, anxiety, and sleeplessness.
• Long-term efficacy and safety profiles of diazepam, particularly in specific patient populations, require ongoing investigation.

Purpose of the Study:

• To quantify plasma concentrations of diazepam and its active metabolite, nordiazepam, in neurosurgical patients undergoing long-term treatment.
• To evaluate the efficacy and potential for abuse of diazepam in this patient cohort over extended periods.

Main Methods:

• Plasma samples were collected from 108 neurosurgical patients receiving daily diazepam doses (5-40 mg) for one month to 16 years.
• Diazepam and nordiazepam concentrations were measured using validated analytical techniques.
• Patient-reported benefits and adverse events were recorded, acknowledging potential confounding factors from concomitant medications.

Main Results:

• Total diazepam-nordiazepam concentrations ranged from 0 to 2,584 ng/mL, with nordiazepam as the predominant metabolite.
• Low concentrations (<250 ng/mL) were observed in 35 patients, and high concentrations (>900 ng/mL) in 20 patients.
• No clear evidence of diazepam abuse was detected, and the drug appeared to maintain efficacy even with prolonged use.

Conclusions:

• Diazepam demonstrates sustained therapeutic benefit and a low risk of abuse in neurosurgical patients, even with treatment durations extending up to 16 years.
• Plasma concentration monitoring may be useful, as nordiazepam is the primary metabolite and levels can vary significantly among individuals.
• Further research is warranted to fully elucidate the long-term pharmacokinetic and pharmacodynamic properties of diazepam in diverse clinical settings.